ATC Group: N07AX03 Cevimeline

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07AX03 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07A Parasympathomimetics
4 N07AX Other parasympathomimetics
5 N07AX03

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 90 mg

Active ingredients in N07AX03

Active Ingredient Description
Cevimeline

Cevimeline is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.

Related product monographs

Title Information Source Document Type  
EVOXAC Capsule FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Japan (JP)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.